At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas
In Brief
A Phase 3 clinical trial evaluating JNJ-77242113 and Placebo for Plaque Psoriasis. Active but no longer recruiting, targeting 311 participants across 90 sites in 11 countries.
Signals
Detailed Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
Study Details
Timeline
Arms & Interventions
Participants will receive JNJ-77242113 from Week 0 through Week 156.
Participants will receive placebo from Week 0 through Week 16 and thereafter will receive JNJ-77242113 from Week 16 through Week 156.
Interventions
JNJ-77242113 will be administered orally.
Placebo will be administered orally.